Go to
current issue
-
The global dimension of Parkinson's disease genetics Lancet Neurol. (IF 46.5) Pub Date : 2024-10-21 Thomas Gasser
No Abstract
-
Uncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic Lancet Neurol. (IF 46.5) Pub Date : 2024-10-21 Shen-Yang Lim, Ai Huey Tan, Azlina Ahmad-Annuar, Njideka Ulunma Okubadejo, Katja Lohmann, Huw R Morris, Tzi Shin Toh, Yi Wen Tay, Lara M Lange, Sara Bandres-Ciga, Ignacio Mata, Jia Nee Foo, Esther Sammler, Joshua Chin Ern Ooi, Alastair J Noyce, Natascha Bahr, Wei Luo, Rajeev Ojha, Andrew B Singleton, Cornelis Blauwendraat, Christine Klein
Knowledge on the genetic basis of Parkinson's disease has grown tremendously since the discovery of the first monogenic form, caused by a mutation in α-synuclein, and with the subsequent identification of multiple other causative genes and associated loci. Genetic studies provide insights into the phenotypic heterogeneity and global distribution of Parkinson's disease. By shedding light on the underlying
-
Changing the landscape of neurological education Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Lukas Sveikata, Indrit Bègue, Raphael Guzman, Luca Remonda, Claudio LA Bassetti
No Abstract
-
Dementia-related stigma is still pervasive Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16
No Abstract
-
A new standard for thrombolysis in acute ischaemic stroke Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Lina Palaiodimou, Georgios Tsivgoulis
No Abstract
-
Changing multiple-sclerosis-induced thoughts and behaviours Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Heleen Beckerman, Vincent de Groot
No Abstract
-
A new era of drug discovery for amyotrophic lateral sclerosis Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Jinsy A Andrews
No Abstract
-
Type I interferonopathies with CNS symptoms Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Shyamala Mani, Angela M Kaindl
No Abstract
-
Multidisciplinary care for rare neurological diseases in China Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Xin-Yuan Chen
No Abstract
-
Neurology crisis in Ethiopia: imbalances in training and retention Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Blen M Gebresilassie, James H Bower, Mehila Zebenigus
No Abstract
-
Dealing with the reproducibility crisis in neuroscience from the grassroots Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Arpan R Mehta
No Abstract
-
Jules Froment's neurological statuettes Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Hugo Ardaillon, Mélia Virely, Peggy Leplat-Bonnevialle, Jérôme Honnorat, Stéphane Thobois
No Abstract
-
Correction to Lancet Neurol 2024; 23: 1086 Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16
Morgan J. Learning to be an adult with a disability. Lancet Neurol 2024; 23: 1086—In this In Context film review, the first sentence should read “21-year-old Samuel Habib has a rare genetic neurodevelopmental disorder, which was diagnosed in 2019 as being caused by mutations in the GNAO1 gene.” This correction has been made to the online version as of Oct 16, 2024, and the printed version is correct
-
Rustam Al-Shahi Salman: balancing depth and breadth with intracerebral haemorrhage Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Jennifer Thorley
No Abstract
-
-
Supporting young carers across neurological disorders Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Melinda S Kavanaugh
No Abstract
-
Head impacts in elite professional football: a growing concern Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Irina Martín-Izquierdo, Mónica Serradell, Bernat Nadal, Irene Madurga, Alex Iranzo
No Abstract
-
Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Keith W Muir, Gary A Ford, Ian Ford, Joanna M Wardlaw, Alex McConnachie, Nicola Greenlaw, Grant Mair, Nikola Sprigg, Christopher I Price, Mary Joan MacLeod, Sofia Dima, Marius Venter, Liqun Zhang, Eoin O’Brien, Ranjan Sanyal, John Reid, Laszlo K Sztriha, Syed Haider, William N Whiteley, James Kennedy, Chris Douglass
BackgroundTenecteplase has potential benefits over alteplase, the standard agent for intravenous thrombolysis in acute ischaemic stroke, because it is administered as a single bolus and might have superior efficacy. The ATTEST-2 trial investigated whether tenecteplase was non-inferior or superior to alteplase within 4·5 h of onset. MethodsWe undertook a prospective, randomised, parallel-group, open-label
-
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Tiffany J Braley, Dawn M Ehde, Kevin N Alschuler, Roderick Little, Yee To Ng, Yuqi Zhai, Gloria von Geldern, Ronald D Chervin, Deirdre Conroy, Thomas R Valentine, Andrew R Romeo, Nicholas LaRocca, Maysa Hamade, Allison Jordan, Mini Singh, Benjamin M Segal, Anna L Kratz
BackgroundFatigue is one of the most disabling symptoms reported by people with multiple sclerosis. Although behavioural and pharmacological interventions might be partly beneficial, their combined effects have not been evaluated for multiple sclerosis fatigue, or examined with sufficient consideration of characteristics that might affect treatment response. In this comparative effectiveness research
-
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Jan C Koch, Andreas Leha, Helen Bidner, Isabell Cordts, Johannes Dorst, René Günther, Daniel Zeller, Nathalie Braun, Moritz Metelmann, Philippe Corcia, Elisa De La Cruz, Patrick Weydt, Thomas Meyer, Julian Großkreutz, Marie-Hélène Soriani, Shahram Attarian, Jochen H Weishaupt, Ute Weyen, Josua Kuttler, Gabriela Zurek, Paul Lingor
BackgroundFasudil is a small molecule inhibitor of Rho-associated kinase (ROCK) and is approved for the treatment of subarachnoid haemorrhage. In preclinical studies, fasudil has been shown to attenuate neurodegeneration, modulate neuroinflammation, and foster axonal regeneration. We aimed to investigate the safety, tolerability, and efficacy of fasudil in patients with amyotrophic lateral sclerosis
-
CNS disease associated with enhanced type I interferon signalling Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Yanick J Crow
The ability to mount an interferon-mediated innate immune response is essential in protection against neurotropic viruses, but antiviral type I interferons also have neurotoxic potential. The production of type I interferons can be triggered by self-derived nucleic acids, and the brain can be susceptible to inappropriate upregulation of type I interferon signalling. Homoeostatic dysregulation of type
-
The European expertise network for open microvascular surgery Lancet Neurol. (IF 46.5) Pub Date : 2024-10-13 Victor Volovici, Marco Cenzato, Torstein R Meling
No Abstract
-
Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial Lancet Neurol. (IF 46.5) Pub Date : 2024-09-19 Suvankar Pal MD, Jeremy Chataway PhD, Robert Swingler MD, Malcolm R Macleod PhD, Neil O Carragher PhD, Giles Hardingham PhD, Bhuvaneish Thangaraj Selvaraj PhD, Colin Smith MD, Charis Wong PhD, Judith Newton MSc, Dawn Lyle BSc, Amy Stenson MSc, Rachel S Dakin PhD, Amarachi Ihenacho MPH, Shuna Colville MPH, Arpan R Mehta PhD, Nigel Stallard PhD, James R Carpenter DPhil, Richard A Parker MSc, Catriona
Motor neuron disease represents a group of progressive and incurable diseases that are characterised by selective loss of motor neurons, resulting in an urgent need for rapid identification of effective disease-modifying therapies. The MND SMART trial aims to test the safety and efficacy of promising interventions efficiently and definitively against a single contemporaneous placebo control group.
-
Evobrutinib in multiple sclerosis: challenges and unmet goals Lancet Neurol. (IF 46.5) Pub Date : 2024-09-19 Anneke van der Walt
-
Trial designs for motor neuron disease in the 21st century Lancet Neurol. (IF 46.5) Pub Date : 2024-09-19 Steve Vucic
-
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials Lancet Neurol. (IF 46.5) Pub Date : 2024-09-19 Prof Xavier Montalban MD, Prof Patrick Vermersch MD, Prof Douglas L Arnold MD, Prof Amit Bar-Or MD, Prof Bruce A C Cree MD, Prof Anne H Cross MD, Prof Eva Kubala Havrdova MD, Prof Ludwig Kappos MD, Prof Olaf Stuve MD, Prof Heinz Wiendl MD, Prof Jerry S Wolinsky MD, Frank Dahlke MD, Claire Le Bolay MSc, Li Shen Loo PhD, Sathej Gopalakrishnan PhD, Yann Hyvert PhD, Andrija Javor MD, Hans Guehring MD,
Evobrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown preliminary efficacy in people with relapsing multiple sclerosis in a phase 2 trial. Here, we aimed to compare the safety and efficacy of evobrutinib with the active comparator teriflunomide in people with relapsing multiple sclerosis.
-
Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18
BackgroundUp-to-date estimates of stroke burden and attributable risks and their trends at global, regional, and national levels are essential for evidence-based health care, prevention, and resource allocation planning. We aimed to provide such estimates for the period 1990–2021. MethodsWe estimated incidence, prevalence, death, and disability-adjusted life-year (DALY) counts and age-standardised
-
RAB32 mutation in Parkinson's disease Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Christian Beetz, Mandy Radefeldt, Kornelia Tripolszki, Krishna Kumar Kandaswamy, Peter Bauer
No Abstract
-
RAB32 mutation in Parkinson's disease Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Edoardo Monfrini, Raffaella Minardi, Franco Valzania, Giovanna Calandra-Buonaura, Paola Mandich, Alessio Di Fonzo
No Abstract
-
RAB32 mutation in Parkinson's disease Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Pilar Gómez-Garre, Miguel Martín-Bórnez, Pablo Mir
No Abstract
-
RAB32 mutation in Parkinson's disease Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Yuwen Zhao, Hongxu Pan, Jifeng Guo, Beisha Tang, Zhenhua Liu
No Abstract
-
Health as a philosophical idea Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Carlos M Madrid-Casado
No Abstract
-
-
Equitable access to levetiracetam for people with epilepsy Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Arjune Sen, Neerja Chowdhary, Asma Hallab, Michele Romoli, J Helen Cross, Bernadette Cappello
-
Considerations for future trials in cerebral cavernous malformations – Authors' reply Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18
-
On the trail of Edinburgh's neuroscience past and present Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Peter Ranscombe
-
Navigating the roads ahead for Alzheimer's disease Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Robert Stirrups
-
Non-inferiority design for trials in multiple sclerosis Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Maria Pia Sormani, Heinz Wiendl
-
Christopher Ross: diseases of the brain, not the mind Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Ray Cavanaugh
-
Considerations for future trials in cerebral cavernous malformations Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Marco Cenzato, Ulrich Sure, Giuseppe Lanzino, Davide Boeris, Torstein Meling, Luca Regli, Andreas Gruber, Peter Vajkoczy, Michael Lawton
-
RAB32 mutation in Parkinson's disease – Author's reply Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Matthew J Farrer
-
Considerations for future trials in cerebral cavernous malformations Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Ali M Alawieh, Hassan Saad, Jonathan A Grossberg, Daniel L Barrow
-
Global burden of stroke: dynamic estimates to inform action Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Simiao Wu, Ming Liu
-
Diagnosis of multiple sclerosis: challenges and opportunities Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Mitchell Wallin
-
Improving access to medicines for neurological disorders Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18
-
Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Lilyana Amezcua, Dalia Rotstein, Afsaneh Shirani, Olga Ciccarelli, Daniel Ontaneda, Melinda Magyari, Victor Rivera, Dorlan Kimbrough, Ruth Dobson, Bruce Taylor, Mitzi Williams, Ruth Ann Marrie, Brenda Banwell, Bernhard Hemmer, Scott D Newsome, Jeffrey A Cohen, Andrew J Solomon, Walter Royal
The differential diagnosis of suspected multiple sclerosis has been developed using data from North America, northern Europe, and Australasia, with a focus on White populations. People from minority ethnic and racial backgrounds in regions where prevalence of multiple sclerosis is high are more often negatively affected by social determinants of health, compared with White people in these regions.
-
Amyloid removal and the appearance of brain volume loss Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Bradley T Hyman
-
Targeting auto-antibodies for CIDP: hope and questions Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Yusuf A Rajabally
-
Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Christopher R S Belder, Delphine Boche, James A R Nicoll, Zane Jaunmuktane, Henrik Zetterberg, Jonathan M Schott, Frederik Barkhof, Nick C Fox
Progressive cerebral volume loss on MRI is a hallmark of Alzheimer's disease and has been widely used as an outcome measure in clinical trials, with the prediction that disease-modifying treatments would slow loss. However, in trials of anti-amyloid immunotherapy, the participants who received treatment had excess volume loss. Explanations for this observation range from reduction of amyloid β plaque
-
Important considerations for children with non-dystrophic myotonia Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Bettina C Henzi, Andrea Klein
-
Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Vinojini Vivekanandam, Iwona Skorupinska, Dipa L Jayaseelan, Emma Matthews, Richard J Barohn, Michael P McDermott, Michael G Hanna
BackgroundNon-dystrophic myotonias are skeletal muscle channelopathies caused by ion channel dysfunction. Symptom onset is frequently in the first decade of life, causing disability in a young cohort. Although there is no cure, symptomatic treatments exist. Previous trials provide evidence of the efficacy of mexiletine. More recently, lamotrigine has been shown to be effective. Both treatments have
-
Differential diagnosis of suspected multiple sclerosis: global health considerations Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Jorge Correale, Andrew J Solomon, Jeffrey A Cohen, Brenda L Banwell, Fernando Gracia, Tirisham V Gyang, Fernando Hamuy Diaz de Bedoya, Mary P Harnegie, Bernhard Hemmer, Anu Jacob, Ho Jin Kim, Ruth Ann Marrie, Farrah J Mateen, Scott D Newsome, Lekha Pandit, Naraporn Prayoonwiwat, Mohammad A Sahraian, Douglas K Sato, Deanna Saylor, Fu-Dong Shi, Kazuo Fujihara
The differential diagnosis of multiple sclerosis can present specific challenges in patients from Latin America, Africa, the Middle East, eastern Europe, southeast Asia, and the Western Pacific. In these areas, environmental factors, genetic background, and access to medical care can differ substantially from those in North America and western Europe, where multiple sclerosis is most common. Furthermore
-
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial Lancet Neurol. (IF 46.5) Pub Date : 2024-09-18 Jeffrey A Allen, Jie Lin, Ivana Basta, Tina Dysgaard, Christian Eggers, Jeffrey T Guptill, Kelly G Gwathmey, Channa Hewamadduma, Erik Hofman, Yessar M Hussain, Satoshi Kuwabara, Gwendal Le Masson, Frank Leypoldt, Ting Chang, Marta Lipowska, Murray Lowe, Giuseppe Lauria, Luis Querol, Mihaela-Adriana Simu, Niraja Suresh, Pieter A van Doorn
BackgroundChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disease of the peripheral nervous system that can lead to severe disability from muscle weakness and sensory disturbances. Around a third of patients do not respond to currently available treatments, and many patients with a partial response have residual neurological impairment, highlighting the need for effective
-
Frailty for neurologists: perspectives on how frailty influences care planning Lancet Neurol. (IF 46.5) Pub Date : 2024-09-11 Marco Canevelli PhD, Caitlin Jackson-Tarlton MD, Kenneth Rockwood MD
The concept of frailty, now being adopted in most medical disciplines, is attracting growing interest in neurology. Every day, most neurologists care for patients with varying degrees of frailty, from very mild to very severe. Frailty exacerbates patients' health needs, complicates clinical decision making, and negatively affects their health outcomes. Increasing evidence suggests that frailty affects
-
Looking beyond the neurological diagnosis: considering frailty Lancet Neurol. (IF 46.5) Pub Date : 2024-09-11 A Jon Stoessl
No Abstract
-
Learning to be an adult with a disability Lancet Neurol. (IF 46.5) Pub Date : 2024-09-10 Jules Morgan
-
The Yaoundé Declaration Lancet Neurol. (IF 46.5) Pub Date : 2024-08-22 Alfred K Njamnshi, Agustin Ibanez, Gagandeep Singh, Mika Pyykko, Vladimir Hachinski, Harris A Eyre
-
Amyloid β, γ-secretase, and familial Alzheimer's disease Lancet Neurol. (IF 46.5) Pub Date : 2024-07-26 Marie-Claude Potier, Harald Steiner, Lucía Chávez-Gutiérrez
-
Endovascular thrombectomy for large ischaemic stroke: outcomes beyond 90 days Lancet Neurol. (IF 46.5) Pub Date : 2024-07-26 Takeshi Morimoto, Fumihiro Sakakibara
-
Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial Lancet Neurol. (IF 46.5) Pub Date : 2024-07-26 Prof Götz Thomalla MD, Prof Jens Fiehler MD, Fabien Subtil PhD, Susanne Bonekamp DVM, Anne Hege Aamodt MD, Prof Blanca Fuentes MD, Prof Elke R Gizewski MD, Prof Michael D Hill MD, Prof Antonin Krajina MD, Prof Laurent Pierot MD PhD, Prof Claus Z Simonsen MD, Prof Kamil Zeleňák MD, Rolf A Blauenfeldt MD, Bastian Cheng MD, Angélique Denis MSc, Prof Hannes Deutschmann MD, Prof Franziska Dorn MD, Fabian
Long-term data showing the benefits of endovascular thrombectomy for stroke with large infarct are scarce. The TENSION trial showed the safety and efficacy of endovascular thrombectomy in patients with ischaemic stroke and large infarct at 90 days. We aimed to investigate the safety and efficacy at 12 months of endovascular thrombectomy in patients who were enrolled in the TENSION trial. TENSION was
更新日期：2024-10-17
Copyright © 2014-2024 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号